LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $1.50 price objective on the stock.

Other analysts have also recently issued research reports about the stock. JMP Securities reaffirmed a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Stock Down 1.6 %

Shares of LVTX stock opened at $1.27 on Monday. LAVA Therapeutics has a 52 week low of $0.85 and a 52 week high of $3.57. The firm has a 50 day moving average of $1.13 and a two-hundred day moving average of $1.36. The stock has a market capitalization of $33.40 million, a PE ratio of -1.23 and a beta of 0.48.

LAVA Therapeutics (NASDAQ:LVTX) last released its earnings results on Friday, March 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.18. The company had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $2.40 million. Analysts expect that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

Institutional Trading of LAVA Therapeutics

Several institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in LAVA Therapeutics during the 3rd quarter worth $32,000. BNP Paribas Financial Markets purchased a new position in shares of LAVA Therapeutics during the fourth quarter worth about $40,000. Finally, Sanofi purchased a new position in shares of LAVA Therapeutics during the fourth quarter worth about $1,825,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.